Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes + Epirubicin in Recurrent NMIBC
NCT06766266Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan liposome injection in bladder urothelial carcinoma (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Bone marrow suppression (Grade four) at 4 weeks. Started Jan 2025; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT06766266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766266.